These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22242967

  • 1. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H, Wu JT, Palmer R, McLean L.
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
    Kosoglou T, Kumar B, Statkevich P, Schiller JE, Kantesaria B, Hanson ME, Sisk CM, Cutler DL.
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
    Niemi M, Backman JT, Neuvonen PJ.
    Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
    [Abstract] [Full Text] [Related]

  • 6. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
    Pedersen RS, Damkier P, Brosen K.
    Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
    [Abstract] [Full Text] [Related]

  • 7. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.
    Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT.
    Drug Metab Dispos; 2016 Aug; 44(8):1364-71. PubMed ID: 27260150
    [Abstract] [Full Text] [Related]

  • 8. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [Abstract] [Full Text] [Related]

  • 9. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T, Backman JT, Neuvonen M, Niemi M, Neuvonen PJ.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [Abstract] [Full Text] [Related]

  • 10. Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
    Kim KA, Park JY.
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):667-73. PubMed ID: 25997544
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers.
    Wittayalertpanya S, Chompootaweep S, Thaworn N, Khemsri W, Intanil N.
    J Med Assoc Thai; 2010 Jun; 93(6):722-8. PubMed ID: 20572378
    [Abstract] [Full Text] [Related]

  • 12. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
    Yeo KR, Kenny JR, Rostami-Hodjegan A.
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1311-20. PubMed ID: 23307233
    [Abstract] [Full Text] [Related]

  • 13. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
    Kim KA, Park PW, Kim KR, Park JY.
    Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
    [Abstract] [Full Text] [Related]

  • 14. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
    Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA.
    Hum Genomics; 2008 Sep; 3(1):7-16. PubMed ID: 19129086
    [Abstract] [Full Text] [Related]

  • 15. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
    LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA.
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):193-202. PubMed ID: 23064958
    [Abstract] [Full Text] [Related]

  • 16. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S, Venkatesh P, Mullangi R, Srinivas NR.
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
    Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U.
    Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
    [Abstract] [Full Text] [Related]

  • 18. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY, Kim KA, Kang MH, Kim SL, Shin JG.
    Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
    [Abstract] [Full Text] [Related]

  • 19. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ.
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [Abstract] [Full Text] [Related]

  • 20. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
    Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ.
    Diabetologia; 2003 Oct; 46(10):1319-23. PubMed ID: 12898007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.